A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders

The investigators employed a phenomenological method with emergent design, conducting in‑depth, semi‑structured interviews to elicit participants' lived ibogaine experiences. Ten US citizens who had undergone ibogaine treatment at Crossroads Treatment Center in Rosarito, Mexico comprised the purposive sample. Interviews were mostly conducted face‑to‑face three days after treatment at the centre; one interview occurred in San Diego three months after that participant's treatment. The sample included three women and seven men, ages 21–48 (mean 28.8 years), with educational attainment ranging from 11th grade to a master's degree; seven participants identified as Caucasian, two as Hispanic, and one as African American. The authors note the sample size (n = 10) is smaller than typical qualitative recommendations but was chosen to enable greater depth per interview. Interview questions were developed by the study team, informed in part by prior research, and are referenced in an Appendix (not provided in the extracted text). Transcripts were analysed using the constant comparative method: themes were identified iteratively across interviews, organised into emergent categories, and refined as analysis progressed. Trustworthiness procedures included a literature review to contextualise findings, frequent debriefing among the primary researcher, co‑authors, and colleagues to surface biases and methodological issues, and transparent outlining of interpretation steps. Ethical oversight was provided by an Institutional Review Board at Alliant International University; participants gave informed consent (including permission to audiotape) and were told they could withdraw at any time. The primary researcher conducted all interviews and had no prior affiliation with the treatment centre.

Analysis generated 13 themes organised into four broad categories: (I) neurological and physical effects, (II) auditory and visual phenomena, (III) alleviation of withdrawal and cravings, and (IV) changed perspectives. A background theme of traumatic histories emerged: 90% of participants reported using substances to cope with traumatic experiences. Category I (neurological and physical effects) emphasised that 80% of participants described their ibogaine experience as physically draining, reporting sensations such as feeling "heavy," "sore," or ‘‘wiped out’’; one participant likened it to having "survived cancer." Half of the sample (5/10) reported impaired psychomotor coordination, dizziness, and/or vomiting, with accounts of difficulty walking and multiple emetic episodes. Category II (auditory and visual phenomena) comprised six themes. Eighty percent of participants reported buzzing or vibration sounds at onset (participants variously described a "bzzzzzz" or ringing). Seventy percent described entering distinct settings or environments during the experience, often with dream‑like quality; content varied widely (examples included hellish scenes, outer space, woodland or tribal camp scenes, womb‑like states, and tunnels with dragons). Sixty percent recounted cyclical or organisational imagery that felt repetitive or served as an anchor (e.g. spinning wheels, slide‑reel repetition, or reorganising memory ‘‘files’’). Eighty percent experienced a mix of dark/scary and joyful/peaceful imagery. Finally, 90% said the experience was difficult to describe or recall in full, reporting rapid, numerous visions that were hard to put into words. Category III (alleviation of withdrawal and cravings) reported unanimous endorsement: 100% of participants described nearly immediate and lasting attenuation of opioid withdrawal symptoms during and after the ibogaine experience, and all participants endorsed minimal to no cravings in the post‑treatment period. Illustrative remarks included surprise at feeling well despite apparent withdrawal and reports that cravings were dramatically shortened or abolished; one participant reported sustained absence of cravings at approximately three months post‑treatment. Category IV (changed perspectives) also showed high consistency: 100% of participants reported increased self‑acceptance and reduced self‑critical thoughts after ibogaine. Seventy percent described a more spiritual outlook, characterised as feelings of connection and meaning. All participants expressed a conviction that ibogaine could help others struggling with opioid problems. Follow‑up contact within six months elicited responses from two participants, both of whom reported doing well and agreed with the themes identified while emphasising the importance of continuing care.

Camlin and colleagues interpret their findings as broadly consistent with prior qualitative ibogaine research while also identifying some differences and novel observations. The authors highlight convergent results: common physical effects (dizziness, motor difficulty, exhaustion, vomiting), frequent visionary/hallucinatory phenomena, and robust attenuation of opioid withdrawal and cravings. They note divergence from prior work in that no participants reported experiencing distinct sequential phases (visionary, evaluation, integration) subjectively, suggesting that such phases may be more apparent to providers than to recipients. The discussion situates the visionary component as often dream‑like and personally meaningful; the authors point to animal EEG findings consistent with rapid‑eye‑movement sleep as supporting evidence and suggest that psychotherapeutic integration techniques used in dream work (for example, Waking Dream Therapy or Jungian analysis) could be considered in future ibogaine‑assisted protocols. The striking and consistent reduction in withdrawal and craving is emphasised as a clinically relevant feature, given the centrality of withdrawal avoidance and craving to ongoing opioid use. Participants' reports of increased self‑acceptance and renewed hope are framed as potentially complementary to cognitive‑behavioural therapies, and the study raises the possibility that ibogaine‑occasioned experiences may increase meaning and spiritual outlook in ways comparable to other psychedelics. The authors acknowledge significant limitations: small sample size (n = 10) limits generalisability; recruitment from a single treatment centre founded by two co‑authors introduces potential selection and confirmation biases; voluntary participation may have oversampled individuals with positive experiences; treatment protocols vary widely across providers, reducing comparability; and the sample was demographically skewed (mostly Caucasian men with Christian backgrounds). To mitigate bias the team included co‑authors described as more sceptical and employed debriefing and transparency measures, but the authors concede these limitations constrain transferability of findings. Building on the results, the authors recommend further research to develop and standardise an ibogaine treatment protocol, suggesting the MDMA‑assisted psychotherapy model as a potential template. They propose investigating structured post‑experience continuing care (including longer‑term CBT, journaling or audio recording to increase retention of visionary content, dream‑work techniques, and elements of logotherapy) to support integration and potentially enhance outcomes. Overall, the authors conclude that ibogaine produced subjectively powerful physiological, emotional, and psychological experiences in this sample and that its consistent attenuation of withdrawal and craving warrants further systematic study and protocol development.